Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1

Metabolism: Clinical and Experimental

Volumn 48, Issue 2, 1999, Pages 252-258

  Burcelin, Rémy ^a   Dolci, Wanda ^a   Thorens, Bernard ^a,b  

^a Dpt Pharmacol and Toxicol   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DRUG ANALOG; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HORMONE BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

EID: 0033005873     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90043-4     Document Type: Article

References (34)

1. DeFronzo RA: The triumvirate: β-Cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687, 1988
2. Kahn CR, Shechter Y: Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas, in Oilman AG, Rail TW, Nies AS. Taylor P (eds): The Pharmacological Basis of Therapeutics. New York, NY, Pergamon. 1990, pp 1463-1494
3. Shimizu I, Hirota M, Ohboshi C, et al: Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 121:1076-1082, 1987
4. Ørskov C: Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35:701-711, 1992
5. Thorens B, Waeber G: Glucagon-like peptide-1 and the control of insulin secretion in the normal state and in NIDDM. Diabetes 42:1219-1225, 1993
6. Mojsov S, Heinrich G, Wilson IB, et al: Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880-11889, 1986
7. Göke R, Conlon JM: Receptors for glucagon-like peptide-1(7-36)amide on rat insulinoma-derived cells. J Endocrinol 116:357-362, 1988
8. Thorens B: Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide I. Proc Natl Acad Sci USA 89:8641-8645, 1992
9. Widmann C, Bürki E, Dolci W, et al: Signal transduction by the cloned glucagon-like peptide-1 receptor. Comparison with signalling by the endogenous receptors of β cell lines. Mol Pharmacol 45:1029-1035, 1994
10. Holst JJ, Ørskov C, Vagn Nielsen O, et al: Truncated glucagon-like peptide 1. an insulin-releasing hormone from the distal gut. FEEB Lett 211:169-174, 1987
11. Mojsov S, Weir GC, Habener JF: Insulinotropin:glucagon-like peptide 1(7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616-619, 1987
12. Weir GC, Mojsov S, Hendrick GK, et al: Glucagon-like peptide 1 (7-37) actions on endocrine pancreas. Diabetes 38:338-342, 1989
13. Drucker DJ, Philippe J, Mojsov S, et al: Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in rat islet cell line. Proc Natl Acad Sci USA 84:3434-3438, 1987
14. Fehmann H-C, Habener JF: Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma bTC-1 cells. Endocrinology 130:159-166, 1992
15. Nathan DM, Schreiber E, Fogel H, et al: Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
16. Gutniak M, Ørskov C, Holst JJ, et al: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
17. Nauck MA, Heimesaat MM, Ørskov C, et al: Preserved incretin activity of glucagon-like peptide 1 (7-36)amide but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307, 1993
18. Nauck MA, Kleine N, Ørskov C, et al: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
19. Ørskov C, Wettergren A, Holst JJ: Biological effects and metabolic rates of glucagon-like peptide-17-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661, 1993
20. Pauly RP, Rosche F, Wermann M, et al: Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of light mass spectrometry. Anovel kinetic approach. J Biol Chem 271:23222-23229, 1996
21. Deacon CF, Nauck MA, Toft-Nielsen M, et al: Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131, 1995
22. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1-(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993
23. Knudsen LB. Pridal L: Glucagon-like peptide-1-(9-39)amide is a major metabolite of glucagon-like peptide-1-(7-36)amide after in vivo administration to dogs, and it acts as an antagonist of the pancreatic receptor. Eur J Pharmacol 318:429-435, 1996
24. Deacon C, Knudsen LB, Madsen K, et al: Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41:271-278, 1998
25. Widmann C, Dolci W, Thorens B: Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate. Mol Endocrinol 10:62-75, 1996
26. Beauvais A, Monod M, Wyniger J, et al: Dipeptidyl peptidase IV secreted by Aspergillus fumigatus, a fungus pathogenic to humans. Infect Immun 65:3042-3047, 1997
27. Gorne RC, Hiens J, Hilse H, et al: Dipeptidyl peptidase activities in various organs of the Wistar rat. Pharmazie 38:112, 1983
28. Gossrau R: Histochemical and biochemical distribution of dipeptidyl peptidase IV. Histochemistry 60:231, 1979
29. Hanski C, Huhle T, Reutter W: Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. J Biol Chem 266:1169-1176, 1985
30. Rachman J, Barrows BA, Levy JC, et al: Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40:205-211, 1997
31. Gutniak MK, Linde B. Holst JJ, et al: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 9:1039-1044, 1994
32. Juntti-Berggren L, Pigon J, Karpe F, et al: The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 19:1200-1206, 1996
33. Todd JF, Wilding JPH. Edwards CMB, et al: Glucagon-like peptide-1 (GLP-1): A trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27:533-536, 1997
34. Gutniak MK, Larsson H, Heiber SJ, et al: Potential therapeutic levels of glucagon-like peptide-1 achieved in human by a buccal tablet. Diabetes Care 19:843-848, 1996